scholarly article | Q13442814 |
P50 | author | Annette Schmitt-Graeff | Q43376014 |
P2093 | author name string | Hubert E Blum | |
Florian Otto | |||
Manfred Olschewski | |||
Oliver G Opitz | |||
Michael Geissler | |||
Jan Harder | |||
Brigitte Weinhold | |||
Oliver Waiz | |||
P2860 | cites work | Role of HER2/neu in tumor progression and therapy | Q28297138 |
Trastuzumab--mechanism of action and use in clinical practice | Q29615810 | ||
Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report | Q33250432 | ||
Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer | Q33372640 | ||
Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. | Q33961881 | ||
Cholangiocarcinoma. | Q33990595 | ||
Oncogene expression in cholangiocarcinoma and in normal hepatic development | Q34668400 | ||
Review article: the modern diagnosis and therapy of cholangiocarcinoma | Q36455955 | ||
HER2 testing in breast cancer: NCCN Task Force report and recommendations. | Q36524447 | ||
Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma | Q36614705 | ||
Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial | Q36614800 | ||
EGFR, HER2 and VEGF pathways: validated targets for cancer treatment | Q36947038 | ||
ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions | Q38455863 | ||
Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry | Q38456543 | ||
Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues | Q38457973 | ||
HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays. | Q40107631 | ||
Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy. | Q40377343 | ||
Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). | Q40809042 | ||
Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma | Q42510917 | ||
Expression of epidermal growth factor receptor in gastric carcinomas | Q44797497 | ||
Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers | Q46488823 | ||
Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study | Q47604705 | ||
Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma | Q48480509 | ||
c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. | Q52122642 | ||
Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver. | Q53496139 | ||
Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours | Q57003964 | ||
Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract | Q71985964 | ||
Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma | Q73653633 | ||
Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study | Q74020609 | ||
Amplification of c-erbB-2 in gastric cancer: detection in formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization | Q74375151 | ||
c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma | Q77581743 | ||
Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer | Q82241194 | ||
P433 | issue | 36 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 4511-4517 | |
P577 | publication date | 2009-09-01 | |
P1433 | published in | World Journal of Gastroenterology | Q15708885 |
P1476 | title | EGFR and HER2 expression in advanced biliary tract cancer | |
P478 | volume | 15 |
Q33683102 | A genetic model for gallbladder carcinogenesis and its dissemination |
Q37639577 | A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers |
Q54222781 | A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status. |
Q26784091 | An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma |
Q100525937 | Application of smart solid lipid nanoparticles to enhance the efficacy of 5-fluorouracil in the treatment of colorectal cancer |
Q34978321 | Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma. |
Q38993903 | Bile acid accelerates erbB2-induced pro-tumorigenic activities in biliary tract cancer |
Q39396785 | Biliary cancer: Utility of next-generation sequencing for clinical management |
Q55364953 | Blocking of the EGFR-STAT3 signaling pathway through afatinib treatment inhibited the intrahepatic cholangiocarcinoma. |
Q42029380 | Cholangiocarcinoma pathogenesis: Role of the tumor microenvironment |
Q37660692 | Cortactin expression confers a more malignant phenotype to gastric cancer SGC-7901 cells |
Q54659121 | Detection of EGFR and COX-2 expression by immunohistochemical method on a tissue microarray section in lung cancer and biological significance |
Q64992326 | Differential Expression of RAGE, EGFR and Ki-67 in Primary Tumors and Lymph Node Deposits of Breast Carcinoma |
Q26771265 | EGFR Signaling in Liver Diseases |
Q36370528 | Evaluation of P53, E-cadherin, Cox-2, and EGFR protein immunoexpression on prognostic of resected gallbladder carcinoma |
Q36582547 | Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma |
Q38812588 | Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). |
Q89556171 | Expression of Female Sex Hormone Receptors, Connective Tissue Growth Factor and HER2 in Gallbladder Cancer |
Q34180209 | Expression of epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxygenase-2, cyclin D1, human epidermal receptor-2 and Ki-67: Association with clinicopathological profiles and outcomes in gallbladder carcinoma |
Q91951546 | Functional and genomic characterization of three novel cell lines derived from a metastatic gallbladder cancer tumor |
Q37794438 | Genetic abberations in gallbladder cancer |
Q37017110 | Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design |
Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
Q91728336 | HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis |
Q90242172 | HER2-targeted therapies - a role beyond breast cancer |
Q39040859 | HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? |
Q54478596 | HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma. |
Q39137066 | Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor. |
Q37439940 | Inhibitor of differentiation proteins do not influence prognosis of biliary tract cancer |
Q47398665 | JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma |
Q39070009 | KRAS Mutation as a Potential Prognostic Biomarker of Biliary Tract Cancers |
Q37307816 | Long non-coding RNA H19 regulates FOXM1 expression by competitively binding endogenous miR-342-3p in gallbladder cancer |
Q42687892 | Molecular alterations and clinical prognostic factors for cholangiocarcinoma in Thai population |
Q38734193 | Multi-OMIC profiling of survival and metabolic signaling networks in cells subjected to photodynamic therapy. |
Q35832274 | Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer |
Q33557258 | Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer |
Q34898080 | Pathological aspects of so called "hilar cholangiocarcinoma". |
Q38331168 | Pathology of gallbladder carcinoma: current understanding and new perspectives |
Q33994406 | Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. |
Q39683530 | Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy |
Q48203761 | Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR. |
Q51075580 | Prognostıc value of increased HER2 expression in cancers of pancreas and biliary tree. |
Q33994814 | Recent advances in the regulation of cholangiocarcinoma growth |
Q27693345 | Role of bile acids in carcinogenesis of pancreatic cancer: An old topic with new perspective. |
Q39382611 | Significance of epithelial growth factor in the epithelial-mesenchymal transition of human gallbladder cancer cells |
Q38849599 | Sulfated Galactans from Red Seaweed Gracilaria fisheri Target EGFR and Inhibit Cholangiocarcinoma Cell Proliferation |
Q34551877 | Systemic Therapy of Cholangiocarcinoma |
Q35357793 | The effect of epiregulin on epidermal growth factor receptor expression and proliferation of oral squamous cell carcinoma cell lines |
Q39422598 | The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines |
Q38132400 | The role of epidermal growth factor receptor in cancer metastasis and microenvironment |
Q26865749 | The significance of genetics for cholangiocarcinoma development |
Search more.